FDA Approves New COPD Medication

The FDA recently approved the first maintenance medication for the treatment of “chronic obstructive pulmonary disease” (COPD), which includes chronic bronchitis and emphysema. Breo Ellipta, which is delivered by inhalation, is taken once a day. The medication contains the corticosteroid fluticasone furoate and vilanterol, which is long acting beta-agonist (LABA). Clinical testing has shown that Breo Ellipta improves lung function and decreases airflow obstruction. It also reduces sudden worsening of COPD symptoms (“exacerbations,” including shortness of breath, cough, and sputum production) among COPD patients with histories of exacerbations. Patients suffering from COPD may want to consult with their doctors about the risks and benefits posed by the new medication if their current medication is not adequately controlling their condition.

If you are diagnosed with chronic obstructive pulmonary disease (COPD), there is a wide range of treatment options available, such as Breo Ellipta. To help you feel better, you and your healthcare provider may need to change your daily habits and routines. We are more than happy to assist you. We invite you to come in and discuss your COPD, our experience and knowledge allows us to always give you the best advice.

HINT: Side effects of the Breo Ellipta medication include increased risk of pneumonia and bone fractures.